500 Internal Server Error

nginx
Infliximab ,Remicade ,CA2 ,TA-650 ,Anti-TNF biologic / TNF inhibitor ,Chimeric monoclonal antibody ,Autoimmune therapeutic / Rheumatology biologic ,Intravenous infusion ,CAS No.170277-31-3
Language
english english français français Italiano Italiano Русский Русский Español Español português português 한국 한국 العربية العربية indonesia indonesia tiếng Việt tiếng Việt ไทย ไทย
Biologics
Biologics

Infliximab ,Remicade ,CA2 ,TA-650 ,Anti-TNF biologic / TNF inhibitor ,Chimeric monoclonal antibody ,Autoimmune therapeutic / Rheumatology biologic ,Intravenous infusion ,CAS No.170277-31-3

Infliximab ,Remicade ,CA2 ,TA-650 ,Anti-TNF biologic / TNF inhibitor ,Chimeric monoclonal antibody ,Autoimmune therapeutic / Rheumatology biologic ,Intravenous infusion ,CAS No.170277-31-3
Trade Name
Remicade
Target
N/A
Molecular Type
Monoclonal Antibody
Sales In 2025 (Millions Of USD)
4100
Product Summary

Trade Name : RemicadeTarget : N/AMolecular Type : Monoclonal AntibodySales in 2025 (Millions of USD) : 4100All detailed product information shall be subject to the issued final COA.Should you need further in-depth documentation for this item, kindly get in touch with us.

Product Description
Detailed Specifications & Features

Trade Name : Remicade
Target : N/A
Molecular Type : Monoclonal Antibody
Sales in 2025 (Millions of USD) : 4100
All detailed product information shall be subject to the issued final COA.
Should you need further in-depth documentation for this item, kindly get in touch with us.

Related Products
quality Bevacizumab ,Avastin ,VEGF ,Anti-VEGF monoclonal antibody ,Anti-VEGF monoclonal antibody ,Humanized IgG1 antibody ,Oncology biologic / Anti-angiogenic therapy ,CAS No.216974-75-3 factory

Bevacizumab ,Avastin ,VEGF ,Anti-VEGF monoclonal antibody ,Anti-VEGF monoclonal antibody ,Humanized IgG1 antibody ,Oncology biologic / Anti-angiogenic therapy ,CAS No.216974-75-3

Trade Name : Avastin Target : VEGF Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us.

quality Vedolizumab ,Entyvio ,MLN0002 ,Anti-integrin biologic ,Humanized IgG1 monoclonal antibody ,IBD therapeutic / Ulcerative colitis biologic / Crohn's disease biologic ,CAS No.943609-66-3 factory

Vedolizumab ,Entyvio ,MLN0002 ,Anti-integrin biologic ,Humanized IgG1 monoclonal antibody ,IBD therapeutic / Ulcerative colitis biologic / Crohn's disease biologic ,CAS No.943609-66-3

Trade Name : Entyvio Target : N/A Molecular Type : N/A Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us.

quality Imiglucerase ,Cerezyme ,rGCR ,GBA (β- glucocerebrosid ase) ,Glycoprotein (This is a protein containing 497 amino acids, produced using recombinant DNA technology) ,CAS No.154248-97-2 factory

Imiglucerase ,Cerezyme ,rGCR ,GBA (β- glucocerebrosid ase) ,Glycoprotein (This is a protein containing 497 amino acids, produced using recombinant DNA technology) ,CAS No.154248-97-2

Trade Name : Cerezyme® Target : GBA (β- glucocerebrosid ase) Molecular Type : Glycoprotein (This is a protein containing 497 amino acids, produced using recombinant DNA technology) Sales in 2025 (Millions of USD) : 1105(estimate) All detailed product information shall be subject to the issued final ...

quality Luspatercept-aamt ,Reblozyl ,ACE-536 ,Recombinant fusion protein ,Activin receptor trap ,Transforming growth factor-β (TGF- β)superfamily ligands ,Recombinant Fusion Protein factory

Luspatercept-aamt ,Reblozyl ,ACE-536 ,Recombinant fusion protein ,Activin receptor trap ,Transforming growth factor-β (TGF- β)superfamily ligands ,Recombinant Fusion Protein

Trade Name : Reblozyl Target : Transforming growth factor-β (TGF- β)superfamily ligands Molecular Type : Recombinant Fusion Protein Sales in 2025 (Millions of USD) : 2000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for ...